JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors

MLA

Kathryn A. F. Pennel, et al. “JAK/STAT3 Represents a Therapeutic Target for Colorectal Cancer Patients with Stromal-Rich Tumors.” Journal of Experimental & Clinical Cancer Research, vol. 43, no. 1, Mar. 2024, pp. 1–20. EBSCOhost, https://doi.org/10.1186/s13046-024-02958-4.

APA

Kathryn A. F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang-Yu Lian, Sara S. F. Al-Badran, Jean A. Quinn, Assya Legrini, Jitwadee Inthagard, Peter G. Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A. Gillespie, Megan Mills, Aula Ammar, Jennifer Hay, Ditte Andersen, Colin Nixon, Selma Rebus, … Joanne Edwards. (2024). JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental & Clinical Cancer Research, 43(1), 1–20. https://doi.org/10.1186/s13046-024-02958-4

Chicago

Kathryn A. F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang-Yu Lian, Sara S. F. Al-Badran, Jean A. Quinn, Assya Legrini, et al. 2024. “JAK/STAT3 Represents a Therapeutic Target for Colorectal Cancer Patients with Stromal-Rich Tumors.” Journal of Experimental & Clinical Cancer Research 43 (1): 1–20. doi:10.1186/s13046-024-02958-4.